Centrosome aberrations have been implicated in the development and progression of breast cancer. Our previous worked show that centrosomal protein 70 (Cep70) regulates breast cancer growth and metastasis. However, it remains elusive whether Cep70 is implicated in the sensitivity of the anti-microtubule drug paclitaxel in breast cancer. Here we provide evidence that Cep70 is a mediator of paclitaxel sensitivity in breast cancer. Cell proliferation assays show that Cep70 expression correlates with paclitaxel sensitivity in breast cancer cell lines. In addition, paclitaxel sensitivity varies when altering Cep70 expression level. Mechanistic studies reveal that Cep70 interacts with tubulin, and promotes the ability of paclitaxel to stimulate microtubule assembly. These data demonstrate that Cep70 mediates paclitaxel sensitivity in breast cancer.
CITATION STYLE
Shi, X., Wang, Y., Sun, X., Wang, C., Jiang, P., Zhang, Y., … Liu, M. (2017). Centrosomal protein 70 is a mediator of paclitaxel sensitivity. International Journal of Molecular Sciences, 18(6). https://doi.org/10.3390/ijms18061267
Mendeley helps you to discover research relevant for your work.